Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.

Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N.

J Clin Oncol. 2019 Jun 1;37(16):1436-1447. doi: 10.1200/JCO.19.00281. Epub 2019 Apr 15.

PMID:
30986117
2.

Prevalence and Severity of Rationing During Drug Shortages: A National Survey of Health System Pharmacists.

Hantel A, Siegler M, Hlubocky F, Colgan K, Daugherty CK.

JAMA Intern Med. 2019 Mar 25. doi: 10.1001/jamainternmed.2018.8251. [Epub ahead of print] No abstract available.

PMID:
30907925
3.

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K.

J Natl Cancer Inst. 2019 Feb 1;111(2):170-179. doi: 10.1093/jnci/djy098.

PMID:
30726946
4.

Imatinib is still recommended for frontline therapy for CML.

Hantel A, Larson RA.

Blood Adv. 2018 Dec 26;2(24):3648-3652. doi: 10.1182/bloodadvances.2018018614. No abstract available.

5.

Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Ou FS, Niedzwiecki D, Zhang S, Fuchs CS, Saltz L, Mayer RJ, Venook A, Ogino S, Song M, Benson A, Hantel A, Atkins JN, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1227-1230. doi: 10.1158/1055-9965.EPI-18-0487. Epub 2018 Jul 23.

PMID:
30038051
6.

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).

Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

PLoS One. 2018 Jul 19;13(7):e0199244. doi: 10.1371/journal.pone.0199244. eCollection 2018.

7.

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.

Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF.

J Immunother Cancer. 2018 Jul 16;6(1):73. doi: 10.1186/s40425-018-0384-0.

8.

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.

Hantel A, Stock W, Kosuri S.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):636-647. doi: 10.1016/j.clml.2018.06.017. Epub 2018 Jun 27. Review.

PMID:
30006258
9.

Creating Coherent Strategies to Combat the Crises of Opioid Scarcity and Abuse.

Hantel A, Levine S, Siegler M.

J Clin Oncol. 2018 Sep 1;36(25):2575-2577. doi: 10.1200/JCO.2018.79.1079. Epub 2018 Jul 12. No abstract available.

PMID:
30001169
10.

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA.

JNCI Cancer Spectr. 2018 Feb;2(2):pky017. doi: 10.1093/jncics/pky017. Epub 2018 May 30.

11.

Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA.

JAMA Oncol. 2018 Jun 1;4(6):783-790. doi: 10.1001/jamaoncol.2018.0126.

12.

A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning.

Bestvina CM, Wroblewski KE, Daly B, Beach B, Chow S, Hantel A, Malec M, Huber MT, Polite BN.

J Palliat Med. 2018 Jun;21(6):846-849. doi: 10.1089/jpm.2017.0408. Epub 2018 Mar 13.

PMID:
29649399
13.

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS.

J Clin Oncol. 2018 Apr 10;36(11):1112-1120. doi: 10.1200/JCO.2017.75.5413. Epub 2018 Feb 28.

14.

Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):438-445. doi: 10.1158/1055-9965.EPI-17-0689. Epub 2018 Jan 22.

15.

Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K.

Ann Oncol. 2017 Jun 1;28(6):1359-1367. doi: 10.1093/annonc/mdx109.

16.

Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.

Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W.

Leuk Lymphoma. 2017 Sep;58(9):1-7. doi: 10.1080/10428194.2017.1289524. Epub 2017 Feb 20.

PMID:
28278716
17.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.

N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.

18.

No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations.

Daly B, Hantel A, Wroblewski K, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN.

J Oncol Pract. 2016 Oct;12(10):e901-e911.

19.

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.

Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL.

J Clin Oncol. 2016 Jan 10;34(2):179-85. doi: 10.1200/JCO.2015.63.9674. Epub 2015 Oct 5. Review.

PMID:
26438111
20.

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2015 Nov 1;33(31):3598-607. doi: 10.1200/JCO.2015.61.5062. Epub 2015 Aug 17.

21.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS.

J Natl Cancer Inst. 2014 Nov 27;107(1):345. doi: 10.1093/jnci/dju345. Print 2015 Jan.

22.

Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use.

Hantel A, Olopade CO.

Ann Intern Med. 2015 Jan 20;162(2):141-2. doi: 10.7326/M14-2002. No abstract available.

PMID:
25322080
23.

A protocol and ethical framework for the distribution of rationed chemotherapy.

Hantel A.

J Clin Ethics. 2014 Summer;25(2):102-15.

PMID:
24972060
24.

Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).

Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA.

PLoS One. 2014 Jun 17;9(6):e99816. doi: 10.1371/journal.pone.0099816. eCollection 2014.

25.

A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies.

Marquez R, Hantel A, Lorenz R, Neistadt B, Wong J, Churpek JE, Mardini NA, Shaukat I, Gurbuxani S, Miller JL, Godley LA.

Leuk Lymphoma. 2014 Dec;55(12):2945-6. doi: 10.3109/10428194.2014.903476. Epub 2014 Apr 22. No abstract available.

26.

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2013 Dec 4;105(23):1789-98. doi: 10.1093/jnci/djt298. Epub 2013 Nov 14.

27.

Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.

Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA.

Clin Colorectal Cancer. 2013 Dec;12(4):233-8. doi: 10.1016/j.clcc.2013.06.005. Epub 2013 Sep 10.

28.

Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.

Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS.

J Natl Cancer Inst. 2012 Nov 21;104(22):1702-11. doi: 10.1093/jnci/djs399. Epub 2012 Nov 7.

29.

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE; American Society of Clinical Oncology.

J Clin Oncol. 2013 Mar 1;31(7):961-5. doi: 10.1200/JCO.2012.45.9859. Epub 2012 Nov 5. Review.

PMID:
23129741
30.

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS.

Clin Cancer Res. 2012 Feb 1;18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246. Epub 2011 Dec 6.

31.

Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.

Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM.

Br J Haematol. 2012 Jan;156(2):196-204. doi: 10.1111/j.1365-2141.2011.08934.x. Epub 2011 Nov 16.

PMID:
22084970
32.

Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.

Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS.

J Natl Cancer Inst. 2011 Oct 19;103(20):1540-51. doi: 10.1093/jnci/djr307. Epub 2011 Aug 17.

33.

Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.

Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Fuchs CS.

J Clin Oncol. 2010 Oct 1;28(28):4354-63. doi: 10.1200/JCO.2010.28.0362. Epub 2010 Aug 30.

34.

A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.

Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK.

Oncology. 2010;78(2):125-9. doi: 10.1159/000312654. Epub 2010 Apr 13.

PMID:
20389134
35.

Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.

McCleary NJ, Niedzwiecki D, Hollis D, Saltz LB, Schaefer P, Whittom R, Hantel A, Benson A, Goldberg R, Meyerhardt JA.

Cancer. 2010 Feb 15;116(4):957-66. doi: 10.1002/cncr.24866.

36.

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.

Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Goldberg RM, Bertagnolli MM, Fuchs CS; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Canadian Cancer Society Research Institute; Southwest Oncology Group.

Clin Cancer Res. 2009 Dec 1;15(23):7322-9. doi: 10.1158/1078-0432.CCR-09-1570. Epub 2009 Nov 24.

37.

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS.

J Clin Oncol. 2009 May 1;27(13):2163-9. doi: 10.1200/JCO.2008.17.4839. Epub 2009 Mar 23.

38.

Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS; Cancer and Leukemia Group B 89803.

J Clin Oncol. 2008 Sep 1;26(25):4109-15. doi: 10.1200/JCO.2007.15.6687.

39.

Association of family history with cancer recurrence and survival among patients with stage III colon cancer.

Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS.

JAMA. 2008 Jun 4;299(21):2515-23. doi: 10.1001/jama.299.21.2515.

40.

Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS.

JAMA. 2007 Aug 15;298(7):754-64.

PMID:
17699009
41.

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ.

J Clin Oncol. 2007 Aug 10;25(23):3456-61.

PMID:
17687149
42.

Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.

Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS.

J Clin Oncol. 2006 Aug 1;24(22):3535-41. Epub 2006 Jul 5.

PMID:
16822843
43.

Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.

Malaisrie SC, Untch B, Aranha GV, Mohideen N, Hantel A, Pickleman J.

Arch Surg. 2004 May;139(5):532-8; discussion 538-9.

PMID:
15136354
44.

Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances.

Voelzke BB, Sakamoto K, Hantel A, Paner GP, Kash J, Waters WB, Campbell SC.

Urology. 2002 Aug;60(2):218-22. Review. No abstract available.

PMID:
12137812
45.

Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.

Clark JI, Kancharla K, Qamar R, Fisher S, Hantel A, Panganiban J, Millbrandt L, Albain KS.

Lung Cancer. 2001 Nov;34(2):271-7.

PMID:
11679186
46.

A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group study 8918.

Malviya VK, Liu PY, Goldberg DA, Hantel A, O'Toole RV, Roach RW, Conrad ME, Alberts DS.

Anticancer Drugs. 1996 Jul;7(5):527-30.

PMID:
8862719
47.

A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.

Albain KS, Liu PY, Hantel A, Poplin EA, O'Toole RV, Wade JL 3rd, Maddox AM, Alberts DS.

Gynecol Oncol. 1995 Jun;57(3):407-11.

PMID:
7774846
48.

A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.

Sosman JA, Flaherty LE, Liu PY, Fletcher W, Thompson JA, Hantel A, Sondak V.

Invest New Drugs. 1995;13(1):83-7.

PMID:
7499114
49.

Phase II trial of piroxantrone in gastric carcinoma. A Southwest Oncology Group study.

Hantel A, Tangen C, Gluck WL, Macdonald JS.

Invest New Drugs. 1994;12(2):159-61.

PMID:
7860236
50.

Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.

Hantel A, Tangen CM, Macdonald JS, Richman SP, Pugh RP, Pollock T.

Invest New Drugs. 1994;12(2):155-7.

PMID:
7860235

Supplemental Content

Loading ...
Support Center